BAUSCH + LOMB CORPORATION Bausch + Lomb Corporation Stock
Equities
BLCO
CA0717051076
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.44 USD | +6.18% |
|
-4.50% | -15.36% |
| May. 06 | Morgan Stanley Upgrades Bausch + Lomb to Overweight From Equalweight, Raises Price Target to $18 From $16 | MT |
| May. 02 | RBC Capital Reviews Bausch + Lomb's Q1 Results | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 4.66B | Sales 2025 * | 4.94B | Capitalization | 4.78B |
|---|---|---|---|---|---|
| Net income 2024 * | -236M | Net income 2025 * | -61M | EV / Sales 2024 * | 1.91 x |
| Net Debt 2024 * | 4.12B | Net Debt 2025 * | 3.8B | EV / Sales 2025 * | 1.74 x |
| P/E ratio 2024 * |
-23
x | P/E ratio 2025 * |
-101
x | Employees | 13,300 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 11.16% |
More Fundamentals
* Assessed data
More news
Latest transcript on Bausch + Lomb Corporation
More recommendations
More press releases
| 1 day | +6.18% | ||
| 1 week | -4.50% | ||
| Current month | -0.69% | ||
| 1 month | -12.22% | ||
| 3 months | +0.98% | ||
| 6 months | -13.06% | ||
| Current year | -15.36% |
1 week
13.16
14.92
1 month
13.1616.55
Current year
13.1617.70
1 year
13.1621.95
3 years
12.2021.95
5 years
12.2021.95
10 years
12.2021.95
| Managers | Title | Age | Since |
|---|---|---|---|
Brenton Saunders
CEO | Chief Executive Officer | 56 | 23-03-05 |
Sam Eldessouky
DFI | Director of Finance/CFO | 51 | 21-12-31 |
Yehia Hashad
CTO | Chief Tech/Sci/R&D Officer | 57 | 22-01-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Brenton Saunders
CEO | Chief Executive Officer | 56 | 23-03-05 |
John Paulson
BRD | Director/Board Member | 68 | - |
Brett Icahn
BRD | Director/Board Member | 44 | 22-06-20 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.40% | 12 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-06 | 14.44 | +6.18% | 1,496,127 |
| 24-05-03 | 13.6 | -1.88% | 533,395 |
| 24-05-02 | 13.86 | +0.87% | 1,157,922 |
| 24-05-01 | 13.74 | -5.50% | 1,718,849 |
| 24-04-30 | 14.54 | -3.84% | 372,167 |
Delayed Quote Nyse, May 06, 2024 at 04:00 pm EDT
More quotes
Bausch + Lomb Corporation is a Canada-based global eye health company. The Companyâs Vision Care segment includes both a contact lens business and a consumer eye care business that consists of contact lens care products, over the counter (OTC) eye drops and eye vitamins. The Companyâs Ophthalmic Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Its Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. The Companyâs brands include PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, and many more.
Calendar
2024-05-29
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
13.6
USD
Average target price
18.71
USD
Spread / Average Target
+37.61%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -15.36% | 4.78B | |
| -4.02% | 184B | |
| -0.75% | 108B | |
| -2.97% | 67.82B | |
| +4.48% | 51.05B | |
| +9.09% | 44.67B | |
| +3.40% | 41.78B | |
| +3.12% | 26.78B | |
| +4.10% | 26.59B | |
| +15.23% | 25.86B |
- Stock Market
- Equities
- BLCO Stock